title: Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.
authors: Rotterdam Cancer Institute, The Netherlands.
authors: G
authors: G
authors: Stoter
authors: E
authors: E
authors: Shiloni
authors: S
authors: S
authors: Gundersen
authors: F J
authors: FJ
authors: Cleton
authors: S
authors: S
authors: Iacobelli
authors: J T
authors: JT
authors: Bijman
authors: P
authors: P
authors: Palmer
authors: C R
authors: CR
authors: Franks
authors: S
authors: S
authors: Rodenhuis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins; D003606:Dacarbazine